系统性过表达IL-22诱导负性免疫调节因子SOCS3并显著减轻小鼠实验性关节炎
该研究在胶原诱导性关节炎(CIA)小鼠模型中,于关节炎发病前通过腺病毒载体局部(关节腔内注射)或系统性(静脉注射)过表达IL-22,评估临床关节炎评分10天。结果显示局部过表达不改变关节炎病理,而系统性过表达显著降低CIA发病率、严重程度和病理,且血清TNF-α和MIP-1α水平降低与脾脏SOCS3表达增强显著相关。
要点
- 系统性过表达IL-22显著减轻CIA小鼠关节炎发病、严重程度和病理。
- 局部关节腔内过表达IL-22不改变关节炎病理。
- 保护效应可能与脾脏负性免疫调节因子SOCS3表达上调相关。
核心结论
- 系统性过表达IL-22在CIA小鼠中具有明确的抗炎作用,可降低疾病发病率、严重程度和病理。
- 系统性IL-22的保护效应可能通过上调负性调节因子SOCS3 orchestrate。
研究设计与样本
- 在DBA-1小鼠中通过免疫和加强注射II型胶原诱导CIA。
- 关节炎发病前,通过腺病毒载体局部(关节腔内注射)或系统性(静脉注射)过表达IL-22,临床关节炎评分持续10天。
- 随后分离关节进行关节炎严重程度组织学分析,并测定滑膜、脾脏和血清中多种炎症介质的mRNA和蛋白表达。
主要发现
- 局部IL-22过表达不改变关节炎病理。
- 系统性IL-22过表达显著降低CIA疾病发病率、严重程度和病理。
- 系统性过表达IL-22的小鼠血清TNF-α和巨噬细胞炎症蛋白1α水平显著降低,且与脾脏负性免疫调节因子SOCS3表达增强显著相关。
临床怎么用
- 系统给予IL-22可能作为实验性关节炎的潜在治疗策略,但尚需临床验证。
- IL-22的局部关节腔作用不影响关节炎病理,提示其治疗效应可能依赖系统性免疫调节。
- SOCS3上调可能是IL-22发挥保护效应的生物标志物或机制靶点。
局限性
- 研究仅在小鼠CIA模型中进行,结果不能直接外推至人类RA。
- IL-22通过腺病毒载体过表达,载体本身的免疫效应可能影响结果解读。
- 机制研究未进一步验证SOCS3上调与保护效应之间的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High levels of IL-22 are present in serum and synovial fluid of patients with RA. As both pro- and anti-inflammatory roles for IL-22 have been described in studies using animal models of RA, its exact function in arthritis remains poorly defined. With this study we aimed to further unravel the mechanism by which IL-22 exerts its effects and to decipher its therapeutic potential by overexpression of IL-22 either locally or systemically during experimental arthritis. METHODS: CIA was induced in DBA-1 mice by immunization and booster injection with type II collagen (col II). Before arthritis onset, IL-22 was overexpressed either locally by intra-articular injection or systemically by i.v. injection using an adenoviral vector and clinical arthritis was scored for a period of 10 days. Subsequently, joints were isolated for histological analysis of arthritis severity and mRNA and protein expression of various inflammatory mediators was determined in the synovium, spleen and serum. RESULTS: Local IL-22 overexpression did not alter arthritis pathology, whereas systemic overexpression of IL-22 potently reduced disease incidence, severity and pathology during CIA. Mice systemically overexpressing IL-22 showed strongly reduced serum cytokine levels of TNF-α and macrophage inflammatory protein 1α that correlated significantly with the enhanced expression of the negative immune regulator SOCS3 in the spleen. CONCLUSION: With this study, we revealed clear anti-inflammatory effects of systemic IL-22 overexpression during CIA. Additionally, we are the first to show that the protective effect of systemic IL-22 during experimental arthritis is likely orchestrated via upregulation of the negative regulator SOCS3.
引用
- Aarts J, Roeleveld DM, Helsen MM, et al. Systemic overexpression of interleukin-22 induces the negative immune-regulator SOCS3 and potently reduces experimental arthritis in mice. Rheumatology (Oxford). 2021. PMID: 33197269. doi:10.1093/rheumatology/keaa589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。